Pharmacielo Announces Issuance Of Cease Trade Order

Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - August 6, 2025) - PharmaCielo Ltd. (TSXV: PCLO) (OTC Pink: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced that the Ontario Securities Commission (the "OSC"), as its principal regulator, has issued a failure to file cease trade order ("FFCTO") prohibiting the trading by any person of any securities of the Company in Canada, including trades in the Company's common shares made through the TSX Venture Exchange ("TSXV").

The FFCTO was issued due to the Company's delay in filing its audited annual consolidated financial statements for the year ended March 31, 2025, the related management's discussion and analysis, and CEO and CFO certificates (collectively, the "Required Documents"), which were due on July 29, 2025, as required by National Instrument 52-109 - Certification of Disclosure in Issuers' Annual and Interim Filings.

The delay in filing has not been because of any material accounting issues, instead, it stems from significant time and resource demands associated with an imminent transaction involving the potential sale of non-core assets. The Company intends to issue a public announcement once the transaction is finalized.

PharmaCielo is working diligently with its accounting staff and its external auditors to complete the outstanding filings and expects to remedy the default shortly. The Company has been advised that the FFCTO will be lifted once the Required Documents are filed.

The Company will issue a further news release once the Required Documents have been filed and the FFCTO has been revoked.

About PharmaCielo
PharmaCielo Ltd. (TSXV: PCLO) (OTC Pink: PCLOF) is a global company, headquartered in Canada, with a focus on ethical and sustainable processing and supplying of all natural, pharmaceutical-grade medical cannabis products to large channel distributors. PharmaCielo's principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its cultivation and processing center located in Rionegro, Colombia.

The board of directors and executive team of PharmaCielo are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia's ideal location plays in building a sustainable business in the medical cannabis industry, and the Company, together with its directors and executives, is executing on a business plan focused on supplying the international marketplace.

MENAFN06082025004218003983ID1109893568